Literature DB >> 8422627

Aggressive osteoblastoma of the calcaneus.

H Miyayama1, K Sakamoto, M Ide, K Ise, K Hirota, T Yasunaga, A Ishihara.   

Abstract

Aggressive osteoblastoma of the left calcaneus in 29-year-old Japanese woman is reported. Her initial symptom was heel pain while walking. This was a primary calcaneal tumor, initially diagnosed as a benign osteoblastoma. After a 5-year follow-up (from the initial curettage), there was local recurrence. The histologic findings of aggressive osteoblastoma were confirmed after right lower leg amputation. The recurrent tumor was mildly aggressive to the talocalcanean joint and the retrocalcaneal area, without distant metastasis. The characteristics of the primary and recurrent tumors were examined by the radiologic, histologic, and electron microscopic procedures. Although there are questions about aggressive osteoblastoma, the authors believe that there are osteoblastic tumors of borderline malignancy between benign osteoblastoma and low-grade osteosarcoma. The current case was an example compatible with an aggressive osteoblastoma with the proposed name of Dorfman classification Group 4.

Entities:  

Mesh:

Year:  1993        PMID: 8422627     DOI: 10.1002/1097-0142(19930115)71:2<346::aid-cncr2820710213>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Chronic Heel Pain Found to Be Diffuse Large B-cell Lymphoma of the Calcaneus.

Authors:  Kevin J Horner; Caitlyn J Smith; Katsiaryna Laziuk; Benjamin Summerhays
Journal:  Cureus       Date:  2022-05-24

2.  Extraosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl.

Authors:  Sabine Danzinger; Leo Kager; Maria Bernathova; Susanna Lang; Werner Haslik; Christian F Singer
Journal:  Clin Case Rep       Date:  2021-03-31

Review 3.  Primary tumours of the calcaneus.

Authors:  Litao Yan; Junwei Zong; Jin Chu; Wendong Wang; Mingshu Li; Xianfeng Wang; Mingzhi Song; Shouyu Wang
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.